{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Germline+BRCA1%2F2+Mutations", "query": { "condition": "Germline BRCA1/2 Mutations" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 23, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Germline+BRCA1%2F2+Mutations&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-22T19:23:17.236Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02561832", "title": "A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Anthracycline", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 15, "start_date": "2015-11-06", "completion_date": "2017-02-01", "has_results": true, "last_update_posted_date": "2019-02-20", "last_synced_at": "2026-07-22T19:23:17.236Z", "location_count": 2, "location_summary": "New York, New York • Stony Brook, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Stony Brook", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02561832" }, { "nct_id": "NCT01945775", "title": "A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms", "BRCA 1 Gene Mutation", "BRCA 2 Gene Mutation" ], "interventions": [ { "name": "talazoparib", "type": "DRUG" }, { "name": "Physician's-Choice", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 431, "start_date": "2013-10-14", "completion_date": "2021-03-05", "has_results": true, "last_update_posted_date": "2022-01-20", "last_synced_at": "2026-07-22T19:23:17.236Z", "location_count": 207, "location_summary": "Flagstaff, Arizona • Scottsdale, Arizona • Antioch, California + 136 more", "locations": [ { "city": "Flagstaff", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Antioch", "state": "California" }, { "city": "Antioch", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01945775" }, { "nct_id": "NCT03286842", "title": "To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HER2-ve Metastatic Breast Cancer", "Germline BRCA1/2 Mutations", "Somatic BRCA1/2 Mutations" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 256, "start_date": "2018-01-17", "completion_date": "2021-10-08", "has_results": true, "last_update_posted_date": "2023-01-17", "last_synced_at": "2026-07-22T19:23:17.236Z", "location_count": 2, "location_summary": "Towson, Maryland • Jackson, Mississippi", "locations": [ { "city": "Towson", "state": "Maryland" }, { "city": "Jackson", "state": "Mississippi" } ], "official_url": "https://clinicaltrials.gov/study/NCT03286842" }, { "nct_id": "NCT03344965", "title": "Olaparib In Metastatic Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer", "Invasive Breast Cancer", "Somatic Mutation Breast Cancer (BRCA1)", "Somatic Mutation Breast Cancer (BRCA2)", "CHEK2 Gene Mutation", "ATM Gene Mutation", "PALB2 Gene Mutation", "RAD51 Gene Mutation", "BRIP1 Gene Mutation", "NBN Gene Mutation" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 114, "start_date": "2018-04-01", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2026-01-05", "last_synced_at": "2026-07-22T19:23:17.236Z", "location_count": 20, "location_summary": "Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03344965" }, { "nct_id": "NCT04890613", "title": "Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "CX-5461", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Senhwa Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2021-09-08", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2026-06-08", "last_synced_at": "2026-07-22T19:23:17.236Z", "location_count": 6, "location_summary": "Santa Monica, California • Tampa, Florida • Boston, Massachusetts + 3 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04890613" }, { "nct_id": "NCT05141708", "title": "Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Metastatic Breast Cancer", "Breast Neoplasms" ], "interventions": [ { "name": "Talazoparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2021-12-17", "completion_date": "2022-06-30", "has_results": true, "last_update_posted_date": "2024-02-16", "last_synced_at": "2026-07-22T19:23:17.236Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05141708" }, { "nct_id": "NCT05806515", "title": "Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Adenocarcinoma", "Stage IIIB Prostate Cancer AJCC v8", "Stage IIIC Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Chest Radiography", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "PSMA PET Scan", "type": "PROCEDURE" }, { "name": "Surgical Procedure", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 44, "start_date": "2024-03-01", "completion_date": "2031-06", "has_results": false, "last_update_posted_date": "2026-01-29", "last_synced_at": "2026-07-22T19:23:17.236Z", "location_count": 133, "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Arroyo Grande, California + 96 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT05806515" }, { "nct_id": "NCT02326844", "title": "BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "BMN 673 (talazoparib)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "FEMALE", "summary": "18 Years to 99 Years · Female only" }, "enrollment_count": 3, "start_date": "2015-03-02", "completion_date": "2016-04-14", "has_results": true, "last_update_posted_date": "2020-08-18", "last_synced_at": "2026-07-22T19:23:17.236Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02326844" }, { "nct_id": "NCT01540565", "title": "Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "BRCA1 Mutation Carrier", "BRCA2 Mutation Carrier", "Ovarian Epithelial Tumor", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Veliparib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 52, "start_date": "2012-04-09", "completion_date": "2018-01-27", "has_results": true, "last_update_posted_date": "2019-07-23", "last_synced_at": "2026-07-22T19:23:17.236Z", "location_count": 153, "location_summary": "Phoenix, Arizona • Concord, California • La Jolla, California + 114 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Concord", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01540565" }, { "nct_id": "NCT02034916", "title": "A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms", "BRCA 1 Gene Mutation", "BRCA 2 Gene Mutation" ], "interventions": [ { "name": "talazoparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2013-12-13", "completion_date": "2018-10-31", "has_results": true, "last_update_posted_date": "2019-10-14", "last_synced_at": "2026-07-22T19:23:17.236Z", "location_count": 37, "location_summary": "Greenbrae, California • Los Angeles, California • Palo Alto, California + 19 more", "locations": [ { "city": "Greenbrae", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02034916" } ] }